-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Enocitabine
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/55726-47-1.gif)
| Category | Cytomegalovirus (CMV) |
| CAS | 55726-47-1 |
| Description | Enocitabine is a nucleoside analog, and is a potent DNA replication inhibitor, and a DNA chain terminator. Enocitabine inhibits the replication of human cytomegalovirus. Enocitabine has antileukemic and antiviral activities. |
Product Information
| Synonyms | N-(1-BETA-D-ARABINOFURANOSYL-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)DOCOSANAMIDE; NSC-239336; SUNRABIN; BEHENOYLCYTOSINE ARABINOSIDE; BH-AC; ENOCITABINE; n-(1-beta-d-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-docosanamid; n(sup4)-behenoyl-1-beta-d-arabinofurano |
| Molecular Weight | 565.78 |
| Molecular Formula | C31H55N3O6 |
| Canonical SMILES | CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)C2C(C(C(O2)CO)O)O |
| Melting Point | 141-142ºC |
| Purity | 98% |
| Density | 1.16g/cm3 |
| Solubility | In Vitro: DMSO : 2 mg/mL(3.53 mM;ultrasonic and warming and heat to 60°C) H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)(insoluble) |
| Appearance | Crystalline Solid |
| Application | An antineoplastic. A derivative of Cytarabine. |
| Storage | Store in original container in a cool dark place. |
| Complexity | 774 |
| Exact Mass | 565.40908648 |
| Index Of Refraction | 1.554 |
| In Vitro | Enocitabine is resistant to deamination because Enocitabine bears a highly lipophilic group at the 4-amino position of the cytosine moiety of cytarabine. The combined effects of Pirarubicin and Enocitabine on HeLa S3 human uterine cervix carcinoma and K562 human myelocytic leukemia cells are determined by enhancement of their cytotoxic activities. Enocitabine or etoposide shows synergistic effects on HeLa S3 and K562 cells. In the presence of Enocitabine, triphosphate forms of the nucleoside analogs are detected in the human cytomegalovirus (HCMV)-infected cells, and synthesis of HCMV DNA is strongly suppressed. |
| PSA | 133.91000 |
| Target | Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; CMV |
| XLogP3-AA | 9.2 |
